Comparing the current results to its competitors, Mereo Biopharma Group Plc reported Revenue decrease in the 1 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 19.19 %, recorded in the same quarter.
Mereo Biopharma Group Plc, slower than the average decrease reported by the company's competitors of -26.24 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -26.24 %
January 8, 2024
Mereo BioPharma, a leading biopharmaceutical company with the chief aim to develop and commercialize innovative therapeutics, has recently provided an update on its formidable pipeline progress and corporate developments. Mereo is setting significant milestones with its strategic focus on rare diseases with the potential to transform the life of patients globally. The company has announced that the Phase 3 part of the Orbit Study and the Phase 3 Cosmic Study of setrusumab for the treatment of Osteogenesis Imperfecta (OI), conducted by its partner Ultragenyx, are expected to complete enrollment around the end of the first quarter and first half of 2024, respectively. This advancement signifies a crucial stage...
Publicly Traded Peers of Mereo Biopharma Group Plc
Jazz Pharmaceuticals Plc Share Performance
+6.50%
This Quarter
Jazz Pharmaceuticals Plc
Profile
Jazz Pharmaceuticals Plc is a biopharmaceutical company focused on developing and commercializing innovative therapies for a range of medical conditions. Their business model revolves around conducting extensive research and development to identify novel molecules and compounds that can address unmet medical needs. By leveraging strategic partnerships, acquisitions, and licensing agreements, they aim to bring these therapies to market and provide valuable treatment options to patients worldwide.
Dianthus Therapeutics Inc is a biotechnology company that focuses on developing novel genetic medicines for patients suffering from rare genetic diseases. Their business model revolves around leveraging cutting-edge gene therapy technologies to design and deliver innovative treatments. By partnering with academic institutions and utilizing a proprietary gene therapy platform, they aim to address unmet medical needs and provide potential new therapies for patients with genetic disorders.
Journey Medical Corporation is a pharmaceutical and medical device company that specializes in developing and commercializing innovative products for dermatology and aesthetics. Their business model revolves around conducting research and development to create new products, acquiring the necessary regulatory approvals, and partnering with healthcare professionals to effectively distribute and market these products. By focusing on dermatology and aesthetics, Journey Medical Corporation aims to address unmet medical needs and provide cutting-edge solutions to improve patient outcomes in these fields.
Sources:
Mereo Biopharma Group Plc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Mereo Biopharma Group Plc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
